Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.
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NAME

Alirocumab and Evolocumab
APPROVED FOR
Lowering of LDL cholesterol in setting of atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or homozygous familial hypercholesterolemia TYPE Alirocumab (humanized IgG1 monoclonal antibody) Evolocumab (humanized IgG2 monoclonal antibody)
MOLECULAR TARGETS
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating serine protease
CELLULAR TARGETS
Circulating PCSK9 secreted from hepatocytes EFFECTS ON TARGETS PCSK9 binds LDL receptor at the surface of hepatocytes, thereby preventing its recycling and enhancing its degradation in endosomes/lysosomes. PCSK9 inhibitors block this interaction, leading to more LDL receptors at the cell surface and enhanced LDL cholesterol clearance from plasma. 
40-59
Age (Years)
60-79 80+
Coronary heart disease accounts for
of every 7 deaths
Human PCSK9 mutations linked to autosomal-dominant familial hypercholesterolemia
2003
Screen for a new mammalian PC leads to the discovery of the ninth member of the family, known as PC subtilisin kexin 9 (PCSK9) 
